drugset / Trial / NCT00751556

Single/Multiple Dose Bioavailability Trial

NCT00751556

Phase 1 Completed 32 enrolled Bayer
RandomizedCrossoverOpen-labelTreatment

Summary

To determine the pharmacokinetic profile of an extended release tablet of naproxen sodium 660 mg relative to the established commercial Aleve 220 mg tablet following single dose administration and at steady-state following multiple dose administration for 4 days.

Timeline

Start
2008-02
Primary completion
2008-03
Completion
2008-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Naproxen Small molecule 220 mg
Subject Naproxen Small molecule 660 mg

Indications

No indication recorded.